Objective. The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome. In this study, we investigated whether oral administration of an NLRP3 inhibitor would be effective to attenuate the symptoms of gout.
Introduction
Gout prevalence has approximately doubled over the past two decades [1] . The age-adjusted annual incidence of gout has also increased dramatically over the past two decades (from 45 to 62.3/100 000) [2] . The rising prevalence of gout is attributed to longevity, use of diuretics and low-dose aspirin, obesity, end-stage renal disease, hypertension and metabolic syndrome [3, 4] . Gout is a common disease characterized by the deposition of monosodium uric acid (MSU) crystals in the joints or subcutaneous tissues, causing acute inflammatory flares or chronic arthritis [5] . MSU crystal-induced acute gout attacks are characterized by IL-1b-driven acute inflammation, fever and intense pain caused by neutrophil accumulation and activation in joints [6] . It is now well established that inflammatory gout attacks caused by MSU crystals are mediated by the activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome in myeloid cells, causing the release of bioactive IL-1b and IL-18 [7] . Therefore, the NLRP3 inflammasome and IL-1b are considered crucial players in the gout inflammatory pathway [8] .
Germline-encoded pattern recognition receptors are responsible for the activation of innate and adaptive immune responses against conserved microbial structures called pathogen-associated molecular patterns or danger signals called danger-associated molecular patterns released by injured cells [9, 10] . The NLRP3 inflammasome is composed of NLRP3, Apoptosis-associated speck-like protein containing a CARD (ASC) and pro-caspase-1. The activation of the inflammasome is induced by bacteria, toxins, adenosine triphosphate (ATP) and MSU crystals and accompanied by the assembly of NLRP3ASCpro-caspase-1, leading to the activation of pro-caspase-1 to produce active caspase-1 [11, 12] . Active caspase-1 cleaves pro-IL-1b to its mature and active form, IL-1b, which is secreted into the extracellular matrix [13] .
A natural dietary isothiocyanate derivative, sulforaphane (1-isothiocyanato-4-methylsulfinylbutane; SFN), is abundant in cruciferous vegetables, such as broccoli and cabbage [14] . We reported that SFN inhibited Toll-like receptor 4 signalling through the suppression of receptor oligomerization by directly binding to cysteine in MD2 [15, 16] . In addition, SFN blocked the activation of the NLRP3 inflammasome in hepatocytes [17] . These findings prompted us to investigate whether SFN may be effective to alleviate gouty inflammation in two gout mouse models stimulated with MSU crystals. The results of the present study may provide a novel therapeutic and preventive strategy for acute gout using an NLRP3 inflammasome inhibitor.
Methods

Animals and cell culture
Ethical approval was obtained for this study from the Institutional Animal Care and Use Committee of the Catholic University of Korea (Permission No. 2012-5-001 and 2014-007). The animal care and experimental protocols were in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Catholic University of Korea. C57BL/6 mice were purchased from OrientBio (South Korea) and acclimated under specific pathogen-free conditions in an animal facility for at least 1 week before experiments. The mice were housed in a room controlled for temperature (23 ± 3 C) and relative humidity (4060%).
Bone marrow was isolated from the C57BL/6 mice as described previously [18] . Isolated bone marrow cells were cultured in DMEM containing 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin, 100 mg/ml streptomycin and 20% L929 conditioned medium for 7 days. Adherent cells were used as macrophages. Cells were maintained at 37 C in a 5% CO 2 /air environment. HEK293T cells (human embryonic kidney cells) were cultured in DMEM containing 10% (v/ v) fetal bovine serum (Invitrogen), 10 000 U/ml penicillin, and 10 000 mg/ml streptomycin.
Reagents
Purified lipopolysaccharides (LPS) from Escherichia coli was obtained from List Biological Laboratories Inc. (Campbell, CA, USA) and dissolved in endotoxin-free water from Sigma-Aldrich (St Louis, MO, USA). ATP and MSU crystals were obtained from Invivogen (San Diego, CA, USA). 2 0 ,7 0 -Dichlorodihydrofluorescein diacetate was purchased from Invitrogen. SFN, nigericin, N-acetyl-L-cysteine (NAC), diphenyleneiodonium, poly(dA:dT), and 4 0 ,6-diamidino-2-phenylindole were obtained from SigmaAldrich. Antibodies directed against caspase-1 and ASC were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Carbobenzoxy-valyl-alanyl-aspartyl-(Omethyl)-fluoromethylketone (Z-VAD-FMK) was obtained from EMD Millipore (Billerica, MA, USA). Antibody directed against IL-1b was obtained from R&D Systems (Minneapolis, MN, USA). Anti-NLRP3 antibody was purchased from Adipogen (San Diego, CA, USA). A caspase-1 activity kit for animal tissues was purchased from Abcam (Cambridge, MA, USA).
Acute gout in mice C57BL/6 mice (78 weeks old) were orally administered 0.2 ml of sterilized water containing SFN (1, 5, 10, 30 mg/ kg), colchocine (3 mg/kg) or vehicle (0.02% dimethyl sulfoxide). After 1 h, MSU crystals (2 mg/ml in 20 ml of sterile, endotoxin-free PBS) or PBS was subcutaneously injected under the plantar surface of the right paw [18] . The foot thickness was monitored over time. Twenty-four hours after injecting the MSU crystals, the foot tissues were homogenized in RIPA buffer, and the supernatants were collected for myeloperoxidase (MPO) assays, immunoblot assays, and ELISAs. For histological analysis, sagittal sections of the footpads were fixed in 10% paraformaldehyde and stained with hematoxylin and eosin.
MPO activity assay MPO activity was determined as a quantitative measurement of neutrophil sequestration in air pouch lavages and footpad tissue homogenates using a MPO colorimetric activity assay kit (Bio-vision, Milpitas, CA, USA) according to the manufacturer's instructions.
Immunoblot analysis for caspase-1 and IL-1b Cell cultured supernatants were concentrated by methanolchloroform protein precipitation. A cell culture supernatant:methanol:chloroform (4:4:1 ratio) mixture was vortexed and centrifuged for 10 min at 20 000 g. The clear upper phase was discarded, and methanol was added to the interphase. The mixture was centrifuged for 10 min at 20 000 g, and the liquid phase was removed. The protein pellet was dried, resuspended with 1Â sample loading buffer, and then incubated for 30 min at 37 C. Equal volumes of sample were resolved by SDSPAGE and electrotransferred to polyvinylidene difluoride membranes. The membranes were blocked to prevent non-specific binding and incubated with corresponding primary antibody and secondary antibody conjugated to horseradish peroxidase. Pro-caspase-1 and caspase-1(p10) were detected by anti-caspase-1 antibody from Santa Cruz Biotechnology. Pro-IL-1b and IL-1b were detected by anti-IL-1b antibody from R&D Systems. The relative bands were visualized with an enhanced chemiluminescence-based detection method.
Caspase-1 activity assay
In vitro caspase-1 activity was measured using a fluorometric caspase-1 assay kit with recombinant human caspase-1 (Bio-vision) according to the manufacturer's instructions. Fluorescence was recorded at 400 nm after excitation at 505 nm with a SpectraMaxM5 (Molecular Devices, Sunnyvale, CA, USA).
ELISA
Levels of IL-1b and TNF-a were determined using ELISA kits (R&D Systems) according to the manufacturer's instructions.
Air pouch gout model
An air pouch was produced by subcutaneous injection of 5 ml of sterile air into the back of the C57BL/6 mouse, followed by injection of 5 ml of sterile air after 3 days. On day 6, MSU crystals (3 mg/ml in PBS/mouse) were injected into the air pouch. After 6 h, the air pouch fluids were harvested with 2 ml of PBS containing 5 mM EDTA. The air pouch fluids were centrifuged at 135 g for 10 min, and the supernatants were analysed for IL-1b by ELISA, caspases-1 activity and MPO activity.
Determination of ASC oligomerization
Insoluble ASC oligomers were isolated from the soluble cell lysate and incubated with a protein crosslinking agent, disuccinimidyl suberate, as previously described [19] . The samples were resolved by SDSPAGE and processed for immunoblotting.
Confocal microscopy analysis
Confocal microscopy analysis was performed as previously described [17] . Briefly, bone-marrow-derived macrophages were fixed with cold methanol and stained with an anti-ASC antibody and fluorescein isothiocyanateconjugated secondary antibody for the detection of ASC oligomers. Images were acquired with a Zeiss LSM710 confocal microscope and Zen2010 software (Carl Zeiss, Oberkochen, Germany).
Transfection and luciferase assays A pcDNA 3.1 nV5-hNLPR3 expression plasmid was a gift from You-Me Kim (Pohang University of Science and Technology, Pohang, South Korea). Expression plasmids for ASC and caspase-1 were gifts from Giulio SupertiFurga (Austrian Academy of Sciences, Vienna, Austria). An iGLuc plasmid was kindly provided by Veit Hornung (University of Bonn, Bonn, Germany). Transient transfection and luciferase assays were performed as previously described [20] .
Determination of reactive oxygen species production LPS-primed bone-marrow-derived macrophages were pretreated with SFN or NAC for 1 h in the presence of the reactive oxygen species (ROS)-specific fluorescent probe 2 0 ,7 0 -dichlorodihydrofluorescein diacetate. After 1 h, the cells were stimulated with inflammasome stimuli, ATP or MSU, for 1 h. Next, the cells were washed with PBS. Fluorescence was assessed with a fluorescence plate reader (excitation, 480 nm; emission, 535 nm). At least three independently stimulated wells were analysed per experiment.
Statistical analysis
Statistical analysis was performed using the software Prism 7 (GraphPad Software, San Diego, CA, USA). All data are expressed as the mean (S.E.M.) and analysed by one-way analysis of variance followed by Tukey's multiple comparison test after being tested for differences in their variance with the BrownForsythe test to ensure that groups of data with unequal sample sizes had similar variances. Based on data from previous projects and preliminary experiments, we calculated the sample size using G*Power 3.1.9.2 to ensure adequate power of the key experiments in detecting prespecified effect sizes. Values of P < 0.05 were considered statistically significant.
Results
Oral administration of SFN attenuated acute gout symptoms induced by uric acid crystals To determine whether SFN attenuated acute gout symptoms, MSU crystals were injected into the right footpad of mice after oral administration of SFN. Oral administration of SFN (30 mg/kg) reduced the increased foot thickness caused by MSU crystals (Fig. 1A and B) . SFN also blocked MSU-crystal-induced recruitment of neutrophils to foot tissues as shown by the analysis of MPO activity in foot tissue homogenates (Fig. 1C) . We determined doseresponse of SFN with lower dosage ranges and confirmed that increase of foot thickness and MPO activity was suppressed by SFN in a dose-dependent manner ( Fig. 1D and  E) . Colchicine, used as a positive control, was effective to reduce the gain of foot thickness and MPO activity induced by MSU crystals (Fig. 1D and E) . These results show that oral administration of SFN alleviated the acute gout symptoms induced by MSU crystals.
MSU crystals induce degradation of pro-caspase-1 to caspase-1(p10), which leads to the activation of caspase-1 activity, and cleavage of pro-IL-1b to IL-1b, which enables the secretion of IL-1b to the extracellular compartment.
Therefore, caspase-1 activation and IL-1b secretion are considered as the hallmarks of NLRP3 inflammasome activation. SFN blocked MSU-crystal-induced degradation of pro-caspase-1 to caspase-1(p10) and of pro-IL-1b to IL1b in foot tissue homogenates as determined by immunoblotting ( Fig. 2A) . Consistently, caspase-1 enzyme activity in foot tissue homogenates, which was increased by injection of MSU crystals, was decreased by oral administration of 30 mg/kg SFN (Fig. 2B ). In addition, SFN decreased MSUcrystal-induced secretion of IL-1b in foot tissue homogenates as determined by ELISA (Fig. 2C) . Furthermore, the lower dosages of SFN decreased caspase-1 activity and IL-1b secretion in a dose-dependent manner ( Fig. 2D and E). Colchicine also inhibited MSU-crystal-induced IL-1b secretion ( Fig. 2D and E) . In contrast, neither MSU crystal injection nor SFN treatment altered TNF-a levels (Fig. 2F) , indicating that TNF-a may not play an important role in the inflammatory symptoms of uric-acid-crystal-induced gout.
The results indicate that oral administration of SFN suppresses MSU-crystal-induced gouty inflammation in accordance with downregulation of the NLRP3 inflammasome.
SFN inhibits uric-acid-crystal-induced activation of the NLRP3 inflammasome in an air pouch mouse model and in primary mouse macrophages
We further investigated the in vivo inhibitory effect of SFN on the NLRP3 inflammasome using an air pouch mouse model (Fig. 3A) . The injection of MSU crystals into the air pouch resulted in an increase in caspase-1 activity and IL1b levels in the air pouch lavage, while oral administration of SFN decreased caspase-1 activity and IL-1b levels in a dose-dependent manner ( Fig. 3B and C) . The results confirmed that the oral administration of SFN was effective at blocking the activation of the NLRP3 inflammasome in vivo. The suppression of the NLRP3 inflammasome by SFN was well correlated with the decrease in MPO activity in the air pouch lavage (Fig. 3D) . Colchicine, used as a positive control, also suppressed IL-1b secretion and MPO activity induced by MSU crystals (Fig. 3C and D) .
SFN suppressed the MSU-crystal-induced degradation of pro-caspase-1 to caspase-1(p10) and pro-IL-1b to IL1b in primary mouse macrophages as determined by immunoblotting (Fig. 3E) . In addition, MSU-crystal-induced IL-1b secretion was inhibited by SFN in primary mouse macrophages (Fig. 3F) . These results supported the in vivo inhibitory effects of SFN on MSU-crystal-induced NLRP3 inflammasome activation.
SFN inhibits activation of the NLRP3 inflammasome but not the AIM2 inflammasome in primary mouse macrophages In addition to MSU crystals to activate NLRP3 inflammasome in a lysosomal membrane damage-dependent mechanism, there are other NLRP3 activators such as ATP and nigericin with different activation mechanisms. ATP activates the P2X7 receptor on plasma membrane resulting in potassium efflux and nigericin acts as a potassium ionophore to induce the decrease in intracellular potassium levels, leading to maturation of caspase-1 and secretion of IL-1b. To investigate whether SFN inhibited other NLRP3 inflammasome activators, we examined the effects of SFN on NLRP3 inflammasome activation induced by ATP and nigericin, in primary mouse macrophages. SFN blocked the degradation of pro-caspase-1 to caspase-1(p10) and pro-IL-1b to IL-1b induced by other NLRP3 inflammasome activators, ATP and nigericin, in primary mouse macrophages (Fig. 4A) . SFN inhibited IL1b secretion induced by ATP and nigericin in primary mouse macrophages as determined by ELISA (Fig. 4B) . Oligomerization of ASC is another hallmark of inflammasome activation. Confocal microscopy analysis revealed that SFN reduced ATP-or nigericin-induced ASC speckle formation, which represents oligomerization (Fig. 4C) . In addition, SFN suppressed ATP-induced oligomerization of ASC in primary mouse macrophages as determined by immunoblotting (Fig. 4D) . The results show that SFN is able to block the activity of various NLRP3 inflammasome activators.
We examined whether SFN regulated the Absent in melanoma 2 (AIM2) inflammasome. Transfection of macrophages with a repetitive synthetic double-stranded DNA, poly(dA:dT), leads to the production of IL-1b, which is dependent on the AIM2 inflammasome [21] . Poly(dA:dT)-induced production of caspase-1(p10) and IL-1b was not inhibited by SFN (supplementary Fig. S1A and B, available at Rheumatology online). The results show that SFN was not able to block the activation of the AIM2 inflammasome.
SFN inhibits the ligand-independent activation of the NLRP3 inflammasome
To elucidate the mechanism of the inhibitory effects of SFN on the NLRP3 inflammasome, we investigated whether SFN regulated ROS production since ROS are known to be generated by a common pathway using various NLRP3 inflammasome activators, including MSU crystals, ATP and nigericin. While NAC and diphenyleneiodonium reduced ROS levels increased by ATP, SFN did not affect ROS production in primary mouse macrophages (Fig. 5A) . Similarly, SFN did not inhibit MSU-crystal-induced ROS production, whereas NAC completely abolished ROS production in primary mouse macrophages (Fig. 5B) . These results suggest that the inhibitory effects of SFN on NLRP3 inflammasome activation are independent of the ROS pathway.
Thus, we next investigated whether SFN inhibited the ligand-independent activation of the NLRP3 inflammasome. All three components of the NLRP3 inflammasome   FIG. 2 Oral administration of sulforaphane suppresses activation of NLRP3 inflammasome in mouse feet injected with uric acid crystals Mice were orally administered with sulforaphane (SFN) 30 mg/kg (AC and F) and as indicated or colchicine (3 mg/kg) (D and E). After 1 h, monosodium uric acid (MSU) crystals (2 mg/ml in 20 ml of sterile, endotoxin-free PBS) were subcutaneously injected into the right footpad at plantar side. After 24 h, the foot tissues were collected for further analysis. # Significantly different from vehicle (Veh) alone, P < 0.05. *Significantly different from MSU alone, P < 0.05. complex, NLRP3, ASC and pro-caspase-1, were reconstituted in HEK293T cells. The reconstitution of the NLRP3 inflammasome resulted in the cleavage of pro-caspase-1 to caspase-1(p10), which was measured in the cell culture supernatants. SFN blocked the production of caspase-1(p10) (Fig. 6A) . The iGLuc luciferase reporter gene assay is used as another indicator of inflammasome activation [18] . iGLuc luciferase reporter activity was increased by the reconstitution of the NLRP3 inflammasome and downregulated by SFN (Fig. 6B) . These results indicate that SFN inhibits the ligand-independent activation of the NLRP3 inflammasome, suggesting that its inhibitory target may lie in the NLRP3 inflammasome complex. Collectively, our results demonstrate that SFN could be beneficial to prevent gout symptoms by suppressing activation of the NLRP3 inflammasome in macrophages.
Discussion
In this study, our results show that oral administration of SFN protected mice from foot-pad swelling and systemic inflammation induced by MSU crystals by blocking the activation of the NLRP3 inflammasome. Our results suggest that the intake of SFN would be therapeutically beneficial to gout patients by alleviating their inflammatory symptoms. Gout is a chronic disease characterized by recurrent painful gout attacks. Gout has become more prevalent over the past few decades, affecting over 3% of adults in the USA [22] . Acute gout flares are associated with poor health-related quality of life, hospitalization, emergency room visits and increased health care costs [23] . The accumulation of uric acid crystals is the characteristic aetiology of gout [6] . The well-established mechanism of a gout attack is the activation of the NLRP3   FIG. 3 Sulforaphane suppresses activation of the NLRP3 inflammasome in an air pouch mouse model and primary mouse macrophages (A) Experimental scheme. Air pouches were produced on the backs of mice. On day 6, the mice were orally administered with sulforaphane (SFN) or colchicine (3 mg/kg). After 1 h, PBS or monosodium uric acid (MSU) crystals (3 mg/ml in PBS/ mouse) were injected into the air pouch. After 6 h, the air pouch fluids were harvested with 2 ml PBS containing 5 mM EDTA. (BD) They were analysed by (B) caspase-1 enzyme activity assay, (C) ELISA for IL-1b and (D) myeloperoxidase (MPO) activity. For (BD), values are means (S.E.M.) (n = 5 mice). (E and F) Bone-marrow-derived macrophages were primed with LPS (500 ng/ml) for 4 h. After LPS was washed out, the cells were treated with SFN for 1 h and then stimulated with MSU crystals (500 mg/ml) for 6 h. In (E), the cell culture supernatants and cell lysates were immunoblotted for the proteins indicated. In (F), the cell culture supernatants were analysed for secreted IL-1b using ELISA. Values are means (S.E.M.) (n = 3).
# Significantly different from vehicle alone, P < 0.05. *Significantly different from MSU alone,
inflammasome by uric acid crystals. In particular, the activation of macrophages by uric acid crystals leads to the recruitment of neutrophils in an NLRP3-inflammasomedependent manner, accompanied by substantial pain and swelling caused by the accumulation and activation of neutrophils [7] . Our results demonstrate the inhibitory effects of SFN on the NLRP3 inflammasome in macrophages. In addition, our in vivo acute gout study shows that MPO activity in uric-acid-injected foot tissues, which is a representative indicator of neutrophil infiltration into tissues, was decreased by SFN intake. These results indicate that SFN effectively regulates the activation of macrophages by uric acid crystals and the recruitment of neutrophils in an NLRP3-inflammasome-dependent mechanism. MSU crystals, ATP and nigericin are the activators of the NLRP3 inflammasome along different activation pathways. Crystal-induced activation, including that caused by MSU crystals, leads to lysosome rupture and the release of lysosomal proteins to the cytoplasm, causing activation of NLRP3. Extracellular ATP triggers P2X7-dependent pore formation, which induces a potassium efflux, resulting in activation of NLRP3. The activation of NLRP3 by nigericin is also mediated by a potassium efflux in P2X7-independent pore formation. The fact that SFN can suppress the effects of these various stimuli, which have different activation mechanisms, on NLRP suggests that the regulatory target of SFN does not lie in any stimulus-specific pathway such as lysosome rupture, P2X7 or potassium efflux. The activation of the NLRP3 inflammasome is associated with ROS generation, which is a common pathway activated by various NLRP3 inflammasome activators, including MSU crystals, ATP and nigericin. ROS induce a conformational change in a thioredoxin-interacting protein, which activates NLRP3 via an interaction under oxidative stress conditions [24] . SFN is well known as an indirect antioxidant agent that is able to induce cytoprotective enzymes by stabilizing nuclear 
#
Significantly different from vehicle (Veh) alone, P < 0.05. *Significantly different from ATP or nigericin, P < 0.05. ND, not detected. (C) BMDMs were primed with LPS (500 ng/ml) for 4 h. After LPS was washed out, the cells were treated with SFN (10 mM) for 1 h and then stimulated with ATP (5 mM) or nigericin (10 mM) for 1 h. The cells were immunostained for ASC (green). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (blue). The staining was detected by confocal microscopy. Arrows indicate ASC specks. Scale bar=10 mm. (D) BMDMs were primed with LPS (500 ng/ml) for 4 h. After LPS was washed out, the cells were treated with SFN for 1 h and further stimulated with ATP (5 mM) for 1 h. After cell lysates were prepared, insoluble pellets and soluble lysates were analysed by immunoblotting.
factor erythroid 2-related factor 2 [25] . Lee et al. [26] reported that SFN suppressed the generation of mitochondrial ROS, an intracellular trigger of the NLRP3 inflammasome. In contrast, Greaney et al. [27] indicated that SFN-mediated inhibition of inflammasome activation is independent of nuclear factor erythroid 2-related factor 2 and the antioxidant response element pathway. Similarly, our results show that SFN was not able to suppress the ROS levels increased by ATP and MSU crystals, suggesting that the inhibitory effects of SFN on the NLRP3   FIG. 5 The suppression of the NLRP3 inflammasome by sulforaphane is independent of the reactive oxygen species pathway (A and B) Bone-marrow-derived macrophages were primed with lipopolysaccharide (LPS) (500 ng/ml) for 4 h. The cells were pretreated with the oxidative stress indicator 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (10 mM) for 1 h and then further stimulated with adenosine triphosphate (ATP; 5 mM) for 1 h (A) or monosodium uric acid (MSU) crystals (500 mg/ml) for 6 h (B) in the presence or absence of sulforaphane (SFN) (10 mM), N-acetyl-L-cysteine (NAC; 2 mM) or diphenyliodonium (DPI). Reactive oxygen species levels are expressed as fluorescence relative to vehicle (Veh) control. Values are means (S.E.M.) (n = 3).
Significantly different from vehicle alone, P < 0.05. *Significantly different from ATP or MSU alone, P < 0.05.
FIG. 6
Sulforaphane inhibits the ligand-independent activation of the NLRP3 inflammasome (A) HEK293T cells were transfected with expression plasmids for NLRP3 (500 ng), ASC (150 ng) and pro-caspase-1 (150 ng). After 3 h, cell culture media were changed and further incubated with sulforaphane (SFN) for 16 h. Cell culture supernatants and cell lysates were analysed by immunoblotting for the indicated proteins. (B) HEK293T cells were transfected with iGLuc luciferase reporter plasmid and expression plasmids for NLRP3, ASC and pro-caspase-1. After 8 h, the cells were treated with SFN for 16 h. The cells were lysed and analysed for luciferase activity. The data were normalized to the activity of b-galactosidase, which was used as an internal control. Luciferase activity is expressed as relative luminescence to vehicle control. Values are means (S.E.M.) (n = 3).
# Significantly different from vehicle alone, P < 0.05. *Significantly different from NLRP3+ASC+caspase-1, P < 0.05. inflammasome activation are independent of the ROS pathway. Previously, we reported that the suppression of the NLRP3 inflammasome by SFN was mediated by the regulation of the AMP-activated protein kinase-autophagy axis in hepatocytes [17] . In this study, our results further demonstrate that SFN is able to suppress the ligand-independent activation of the NLRP3 inflammasome, indicating that the target of SFN may lie in the NLRP3 inflammasome complex. Taken together, the results of our study suggest that SFN can inhibit NLRP3 inflammasome activity via regulation of the inflammasome complex itself and the AMP-activated protein kinaseautophagy axis.
The activation of the NLRP3 inflammasome consists of two signal steps: signal 1 is the priming step, including the transcription of pro-IL-1b by the activation of downstream signalling pathways of membrane receptors such as Tolllike receptors, while signal 2 includes the activation of NLRP3, leading to the activation of caspase-1 to process pro-IL-1b into IL-1b Although there have been many studies investigating the regulation of the NLRP3 inflammasome by small molecules for disease treatment, some studies have failed to dissect signal 1 from signal 2, only showing the regulation of the signal 1 pathway, including nuclear factor-kB activation. It has been reported that SFN inhibits Toll-like receptor 4 signalling through the suppression of the receptor oligomerization process [15, 16] , showing that SFN affects signal 1. Therefore, to exclude the effects of SFN on signal 1 and to observe its effects on signal 2, SFN was treated after washing with LPS, which is the priming stimulator for signal 1.
Collectively, our results present a novel therapeutic strategy for treating gout using small molecules that target the NLRP3 inflammasome. Activation of the NLRP3 inflammasome is well known to be a critical event in the development of crystal-related diseases such as gout by uric acid crystals [7] and silicosis by silica [28] . In addition, the NLRP3 inflammasome is associated with onset and progression of auto-inflammatory and auto-immune diseases including neurodegenerative diseases (multiple sclerosis, Alzheimer's disease and Parkinson's disease) [2934] . Accumulating evidence shows that activation of the NLRP3 inflammasome is implicated in a range of more complex conditions such as metabolic syndrome and associated diseases such as diabetes and atherosclerosis [35] . Therefore, our results may further suggest a useful application of SFN for NLRP3 inflammasome-associated autoimmune and metabolic diseases such as diabetes, in addition to acute gout.
